SecBot SecBot
PTAB-TRIAL ·Filed Nov 9, 2026

HALO

HALOZYME THERAPEUTICS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed7d 7h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB final written decision
Actionable Insight ▼ Bearish

Monitor Halozyme's next steps: appeal to the Federal Circuit, potential reissue/reexamination, and impact on the parallel district court litigation against Merck. The cancellation of this patent may weaken Halozyme's position in the broader patent family dispute.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$102.98
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.26%
T+1 · $101.68 · next T+5 in 4h
Vs SPY
−2.58%
α at T+1
Latest observation
−5.62%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $102.98entry
  2. T+1 · 6d ago −1.26%α −2.58% · $101.68
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

Executive Summary

The PTAB issued a final written decision in PGR2025-00042, holding all challenged claims (1, 2, 5, and 7–33) of Halozyme's U.S. Patent 12,037,618 unpatentable for lack of written description, lack of enablement, and obviousness. The patent covers modified PH20 hyaluronidase polypeptides, which are central to Halozyme's drug delivery technology platform. This is a material loss for Halozyme, as the patent is part of a broader patent family asserted against Merck in a related district court litigation.

PTAB Trial Details

Proceeding
PGR2025-00042
Proceeding Type
PGR (post-grant review)
Decision
Final written decision
Company Role
Patent owner
Outcome for Patent Owner
Loss
Patent
U.S. 12,037,618
Patent Covers
Modified PH20 hyaluronidase polypeptides, formulations and uses thereof
Challenged Claims
1, 2, 5, 7–33
Claims Cancelled
1, 2, 5, 7–33
Related Litigation
Halozyme, Inc. v. Merck Sharp & Dohme LLC, 2:25-cv-03179 (D.N.J.)
Next Step
Parties seeking judicial review must comply with 37 C.F.R. § 90.2 (appeal to Federal Circuit)

Key Facts

  • Final Written Decision in PGR2025-00042 cancels all challenged claims (1, 2, 5, 7–33) of U.S. Patent 12,037,618 B2
  • Patent covers modified PH20 hyaluronidase polypeptides used in drug delivery
  • Petitioner Merck Sharp & Dohme LLC prevailed on all three grounds: written description, enablement, and obviousness
  • Patent is part of a family of 15+ related patents asserted in Halozyme v. Merck (2:25-cv-03179 D.N.J.)
  • Halozyme's market cap is $14.0B; the patent is core to its technology platform

Financial Impact

Loss of patent protection for a key platform technology; potential impact on licensing revenue and litigation leverage against Merck. Exact financial exposure not stated in the decision.

revenuelicensing_incomelitigation_position

Risk Factors

  • Patent cancellation may reduce Halozyme's bargaining power in licensing negotiations and ongoing litigation
  • Related patents in the same family face similar validity challenges in other PGR proceedings
  • Appeal to the Federal Circuit is possible but uncertain

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-PGR2025-00042-fwd-HALO

Track record

15 reports on HALO

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 9, 20268d ago PTAB Trial Bearish 6/10 Viewing Entry $102.98 Now $96.50 +6.29% settles Nov 17
  2. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  4. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
  5. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
  6. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  7. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  8. Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  9. Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  10. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 49m

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 9, 2026